We are live on
!
Find out more
First Manhattan Portfolio holdings
AUM
$36.1B
1-Year Est. Return
11.5%
This Fund
S&P 500
This Quarter
Est. Return
+9.64%
1 Year Est. Return
+11.5%
3 Year Est. Return
+74.65%
5 Year Est. Return
+103.66%
10 Year Est. Return
+354.63%
AUM
$27.3B
AUM Growth
+$1.22B
(+4.7%)
Cap. Flow
-$932M
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
60.57%
Holding
1,588
New
70
Increased
176
Reduced
495
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$128M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$67.4M |
| 3 |
XIFR
XPLR Infrastructure LP
XIFR
|
+$63.8M |
| 4 |
UnitedHealth
UNH
|
+$57.4M |
| 5 |
Danaher
DHR
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$760M |
| 2 |
Amazon
AMZN
|
+$68.5M |
| 3 |
AbbVie
ABBV
|
+$54.2M |
| 4 |
PPLI
People Inc
PPLI
|
+$36.8M |
| 5 |
PNC Financial Services
PNC
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 44.09% |
| 2 | Technology | 18.28% |
| 3 | Healthcare | 10.34% |
| 4 | Consumer Discretionary | 7.89% |
| 5 | Communication Services | 5.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Blackrock
BLK
$164B
| $785K | ﹤0.01% |
1,136
+161
| +17% | +$108K |
|
402
Vitesse Energy
VTS
$659M
| $776K | ﹤0.01% |
34,645
-10,746
| -24% | -$224K |
|
403
Emerson Electric
EMR
$82.9B
| $776K | ﹤0.01% |
8,583
-829
| -9% | -$69.8K |
|
404
Vanguard FTSE All-World ex-US ETF
VEU
$65.6B
| $774K | ﹤0.01% |
14,234
| – | – |
|
405
Superior Group of Companies
SGC
$193M
| $774K | ﹤0.01% |
82,845
+500
| +0.6% | +$4.2K |
|
406
lululemon athletica
LULU
$13B
| $772K | ﹤0.01% |
2,039
+18
| +0.9% | +$6.64K |
|
|
CET
407
Central Securities Corp
CET
$1.54B
| $768K | ﹤0.01% |
21,019
| – | – |
|
|
HTBK
408
DELISTED
Heritage Commerce
HTBK
| $762K | ﹤0.01% |
92,045
| – | – |
|
409
Nathan's Famous
NATH
$402M
| $760K | ﹤0.01% |
9,675
-3,025
| -24% | -$226K |
|
410
Shell
SHEL
$245B
| $755K | ﹤0.01% |
12,507
+750
| +6% | +$45K |
|
411
Newell Brands
NWL
$2.16B
| $749K | ﹤0.01% |
86,100
+2,700
| +3% | +$26.9K |
|
|
PXD
412
DELISTED
Pioneer Natural Resource Co.
PXD
| $746K | ﹤0.01% |
3,600
| – | – |
|
413
HSBC
HSBC
$355B
| $731K | ﹤0.01% |
18,452
-946
| -5% | -$35.3K |
|
414
Jacobs Solutions
J
$15.9B
| $718K | ﹤0.01% |
7,297
| – | – |
|
|
MRSH
415
Marsh
MRSH
$86.3B
| $710K | ﹤0.01% |
3,776
-809
| -18% | -$144K |
|
416
Clorox
CLX
$11.6B
| $707K | ﹤0.01% |
4,445
-6,540
| -60% | -$1.05M |
|
417
Ark Restaurants
ARKR
| $704K | ﹤0.01% |
38,062
| – | – |
|
418
Bank OZK
OZK
$5.49B
| $703K | ﹤0.01% |
17,500
| – | – |
|
419
Parke Bancorp
PKBK
$390M
| $699K | ﹤0.01% |
41,149
| – | – |
|
420
iShares MSCI Emerging Markets ETF
EEM
$28B
| $697K | ﹤0.01% |
17,617
-400
| -2% | -$15.7K |
|
421
Royal Bank of Canada
RY
$291B
| $695K | ﹤0.01% |
7,280
| – | – |
|
422
Occidental Petroleum
OXY
$57B
| $693K | ﹤0.01% |
11,792
-1,000
| -8% | -$60K |
|
423
Cintas
CTAS
$82.4B
| $689K | ﹤0.01% |
5,548
+4
| +0.1% | +$469 |
|
424
Brink's
BCO
$5.02B
| $683K | ﹤0.01% |
10,069
| – | – |
|
425
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
$66.1B
| $675K | ﹤0.01% |
8,543
+1,031
| +14% | +$81.9K |
|
Similar funds
SAM
First Manhattan's Q2 2023 Portfolio in Review
As of Q2 2023, First Manhattan held 1,588 positions worth $27.3B, up 4.7% from $26.1B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
First Manhattan withdrew a net $932M in Q2 2023, closing 161 positions and reducing 495 holdings. Its most notable exit was Enanta Pharmaceuticals, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 44% of assets, down from 45% a quarter earlier, followed by Technology and Healthcare.
Against the trend, First Manhattan opened a new position in Mersana Therapeutics worth $1.87M.
- First Manhattan's largest Q2 2023 buy was Mersana Therapeutics: 22,784 shares worth $1.87M.
- First Manhattan added most to Thermo Fisher Scientific in Q2 2023, an estimated $128M increase.
- First Manhattan's biggest Q2 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $760M.
- First Manhattan fully exited Enanta Pharmaceuticals in Q2 2023, selling an estimated $10.7M.
- First Manhattan's ten largest holdings make up 61% of its $27.3B portfolio in Q2 2023.
- First Manhattan opened 70 new positions and closed 161 in Q2 2023.
- First Manhattan's portfolio value rose 4.7% quarter-over-quarter to $27.3B.
Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.